Amgevita (adalimumab) Biosimilar | Amgen

You are leaving Amgevita.EU website and entering another Amgen website

You are leaving Amgevita.EU website and entering another Amgen website

You are now leaving Amgevita.EU
Amgen does not endorse or accept liability for sites controlled by third parties

Return to previous page Continue

Countries ▼

What’s behind amgevita®
MAKES THE DIFFERENCE Introducing the citrate-free adalimumab biosimilar from Amgen1 - a proven leader with nearly four decades of experience in biologics and a commitment to inflammation2

AMGEN
Amgen is committed to the treatment of inflammatory diseases and has nearly four decades of experience in the research, development, manufacturing and supply of innovator biologics2
READ MORE ABOUT AMGEN'S EXPERIENCE
Value of biosimilars
Biosimilars may play a potential role in the sustainability of healthcare systems3
READ MORE ABOUT THE BENEFITS OF BIOSIMILARS
Robust totality of evidence
AMGEVITA® demonstrated similarity to Humira® with a totality of evidence that comprised two bioequivalence trials including switch data and long-term safety data in rheumatoid arthritis and plaque psoriasis4-7
READ MORE ABOUT AMGEVITA®'S EVIDENCE
Patient comfort
AMGEVITA® has a citrate-free formulation1
READ MORE ABOUT AMGEVITA®'S ADMINISTRATION
Support & services
Amgen is committed to providing you and your patients with the service and support you need
READ MORE ABOUT AMGEN SERVICE & SUPPORT
  1. AMGEVITA® (adalimumab) Summary of Product Characteristics. Available at: www.ema.europa.eu. Last revised March 2020.
  2. Amgen Biosimilars. Available at: www.amgenbiosimilars.com. Last accessed May 2020.
  3. Taberno J, et al. ESMO Open. 2016;1:e000142.
  4. Cohen S, et al. Ann Rheum Dis. 2017;76:1679–87.
  5. Papp K, et al. J Am Acad Dermatol. 2017;76:1093–102.
  6. Papp K, et al. Br J Dermatol. 2017;177:1562–74.
  7. Cohen S, et al. Arthritis Res Ther. 2019;21:84.
SmPC

footerbg

AMGEVITA® is authorised for the following indications by the European Commission:
AMGEVITA® is an adalimumab biosimilar indicated for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, paediatric plaque psoriasis, hidradenitis suppurativa, Crohn’s disease, paediatric Crohn’s disease, ulcerative colitis, uveitis and paediatric uveitis.
> See full indication
AMGEVITA® (adalimumab) Summary of Product Characteristics. Available at: www.ema.europa.eu. Last revised March 2020.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

The information contained in this website is for European healthcare professionals only

I understand and confirm I am an EU healthcare professional
Read more >
I am not an EU healthcare professional
Read more >
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.